+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, End User, Route Of Administration - Global Forecast to 2030- Product Image
Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, End User, Route Of Administration - Global Forecast to 2030- Product Image
Sale

Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, End User, Route Of Administration - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889014
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peripheral Arterial Disease Therapeutics Market grew from USD 5.14 billion in 2024 to USD 5.60 billion in 2025. It is expected to continue growing at a CAGR of 8.83%, reaching USD 8.55 billion by 2030.

Navigating the Evolving Peripheral Arterial Disease Therapeutics Arena

Peripheral arterial disease represents one of the most pressing vascular health challenges worldwide, impacting patient mobility, quality of life, and healthcare resources. This executive summary lays the foundation for understanding how therapeutic innovation, regulatory shifts, and market dynamics are converging to redefine the treatment landscape. By examining the key forces at play-from novel anticoagulant mechanisms to evolving payer frameworks-this overview equips stakeholders with the context needed to anticipate disruption and identify high-impact opportunities.

Through detailed analysis of technological breakthroughs, tariff implications, segmentation nuances, regional drivers, and competitive strategies, readers will gain a panoramic view of the peripheral arterial disease therapeutics ecosystem. This introduction sets the tone for a data-driven exploration of emerging treatments, strategic imperatives, and actionable recommendations designed to inform investment, policy, and clinical decision-making.

Emerging Innovations Redefine Treatment Paradigms

In recent years, groundbreaking advances have shifted the paradigm of peripheral arterial disease management. A surge in novel anticoagulant molecules and targeted antiplatelet formulations has expanded treatment arsenals beyond traditional warfarin and aspirin regimens. At the same time, the rise of biosynthetic thrombolytics and next-generation vasodilators is enabling more precise control of microvascular flow, thereby improving limb salvage rates.

Concurrently, digital health integration is transforming patient monitoring and adherence programs. Wearable sensors and telehealth platforms now facilitate real-time assessment of walking patterns and perfusion metrics, empowering clinicians to adjust therapy dynamically. Moreover, personalized medicine initiatives are leveraging genomic and biomarker profiling to stratify patients by risk, paving the way for individualized dosing and combination regimens.

These transformative trends are further bolstered by a wave of minimally invasive endovascular interventions, which are increasingly performed in outpatient settings. Consequently, the interplay between pharmacologic innovation and procedural excellence is fostering a more holistic approach to disease management, one that prioritizes both clinical efficacy and patient experience.

Assessing the Ripple Effects of New US Tariff Measures

The introduction of new United States tariffs in 2025 has reverberated across the peripheral arterial disease therapeutics supply chain. Manufacturers relying on imported active pharmaceutical ingredients and specialty excipients have faced elevated input costs, prompting reassessment of sourcing strategies. In turn, some established players have accelerated plans to onshore key production steps, while smaller innovators have sought toll-manufacturing agreements to mitigate exposure to trade policy volatility.

Healthcare systems have experienced upward pressure on drug acquisition expenses, leading hospital procurement teams to negotiate more aggressively with suppliers. In certain cases, tension between cost containment mandates and clinical efficacy requirements has spurred interest in domestically produced alternatives and generic formulations. Payer organizations have responded by tightening formulary inclusion criteria and demanding more robust real-world evidence to justify premium pricing.

Looking ahead, these cumulative tariff effects underscore the importance of supply chain resilience and strategic partnerships. Companies that proactively diversify manufacturing footprints and cultivate transparent logistics networks will be better positioned to weather future trade disruptions and sustain uninterrupted access for patients.

Unveiling Core Patient and Product Segments

A granular understanding of patient and product segmentation is essential to unlocking growth in the peripheral arterial disease sector. When analyzed by product type, anticoagulants emerge as a pivotal category, encompassing direct oral anticoagulants alongside heparin and warfarin derivatives. Equally vital are antiplatelet agents, where cornerstone therapies such as aspirin, clopidogrel, and ticagrelor continue to anchor clinician prescribing. Meanwhile, thrombolytic compounds including tissue plasminogen activator and urokinase maintain a critical role in acute intervention protocols, and vasodilators such as cilostazol and pentoxifylline support improved microvascular perfusion in chronic disease management.

In terms of clinical indication, the market bifurcates between patients facing critical limb ischemia and those experiencing intermittent claudication, each demanding distinct therapeutic intensities and care pathways. From the vantage of end-user environment, ambulatory surgical centers are capitalizing on outpatient procedural efficiencies, hospitals remain the epicenter for acute and complex cases, and specialty clinics provide targeted follow-up and rehabilitation services. Furthermore, the route of administration plays a defining role in treatment adherence and patient convenience, with oral therapies dominating chronic regimens and parenteral options reserved for hospital-based or emergency settings.

Synthesizing these dimensions illuminates where unmet needs intersect with commercial potential, guiding tailored development, clinical trial design, and market access strategies.

Regional Market Dynamics Shaping Future Growth

Regional dynamics are exerting a profound influence on peripheral arterial disease therapeutics adoption and evolution. In the Americas, established reimbursement frameworks and advanced clinical infrastructure support rapid integration of next-generation therapies, while demographic aging trends drive sustained demand for limb preservation solutions. Stakeholders in this region are focused on streamlining hospital workflows and expanding outpatient procedural capabilities to optimize cost-effectiveness.

Across Europe, Middle East and Africa, regulatory heterogeneity shapes product registration timelines and pricing negotiations. In Western Europe, strong health technology assessment bodies enforce rigorous value demonstration, whereas emerging markets in Eastern Europe and the Middle East are prioritizing access expansion and local production partnerships. Africa, with its diverse healthcare landscapes, presents both challenges in distribution logistics and opportunities for innovative access models.

In the Asia-Pacific landscape, growing prevalence of diabetes and smoking correlates with a surge in peripheral arterial disease cases. Governments have responded with initiatives to bolster rural screening programs and subsidize generic pharmaceuticals. Moreover, the rapid expansion of private hospitals and specialty clinics in key markets like China and India is driving broader adoption of advanced anticoagulants and vasodilators.

Leading Players Driving Therapeutic Advancement

Leading pharmaceutical and biotechnology firms are propelling peripheral arterial disease innovation through strategic investment and collaboration. Global heavyweights known for their anticoagulant portfolios have deepened R&D pipelines with next-generation factor XI inhibitors, aiming to deliver enhanced safety profiles and minimized bleeding risk. At the same time, specialty biotech entities are focusing on novel thrombolytic delivery platforms, including micro-emulsion systems that promise more precise targeting of occlusive thrombi.

Partnerships between device manufacturers and pharma companies have given rise to drug-coated balloon catheters and bioresorbable scaffold technologies, illustrating the growing convergence of pharmacotherapy and interventional approaches. Concurrently, mid-size firms are differentiating through patient support programs and digital adherence solutions, seeking to demonstrate real-world outcomes that resonate with payers.

Mergers and acquisitions remain a cornerstone strategy for market consolidation, with larger organizations absorbing niche innovators to broaden their therapeutic scope. Those companies that integrate complementary platforms and streamline regulatory pathways will likely accelerate time-to-market and strengthen their competitive positioning.

Strategic Imperatives for Competitive Advantage

To navigate the complex peripheral arterial disease landscape, industry leaders should prioritize several strategic imperatives. First, diversifying supply chains by establishing dual manufacturing sites and forging regional partnerships can insulate against future tariff shocks and logistic bottlenecks. This approach will not only ensure continuity of supply but also underpin negotiations with payers by demonstrating robust cost management.

Second, investing in combination therapy trials that integrate anticoagulants with emerging antiplatelet regimens or vasodilator protocols can unlock new efficacy benchmarks. Companies that harness real-world evidence platforms to track patient outcomes in ambulatory settings will build compelling value propositions for formulary inclusion. Furthermore, embedding digital health solutions within clinical offerings-such as mobile adherence reminders and remote perfusion monitoring-will strengthen patient engagement and support premium pricing models.

Finally, expanding footprint in high-growth regions requires tailored market access strategies that reflect local regulatory landscapes and healthcare infrastructures. By collaborating with regional health authorities on screening initiatives and leveraging outcomes data to inform reimbursement dossiers, organizations can accelerate adoption and fortify their global leadership positions.

Robust Methodological Framework Underpinning Insights

This analysis draws upon a comprehensive methodology designed to ensure depth, accuracy, and relevance. Primary research included in-depth interviews with key opinion leaders, vascular surgeons, interventional radiologists, and pharmacy directors, providing frontline perspectives on therapeutic efficacy, procedural trends, and patient adherence challenges. Supplementing these insights, structured surveys of procurement managers across hospitals and ambulatory centers captured evolving budgetary priorities and formulary dynamics.

Secondary research comprised rigorous review of peer-reviewed journals, regulatory filings, patent databases, industry white papers, and press releases. Trade association data and conference proceedings from major vascular and cardiology symposia further informed assessments of emerging compounds and device innovations. All data points underwent triangulation and quality checks, ensuring consistency across sources and highlighting areas of consensus and divergence.

The segmentation framework and regional analysis were validated through cross-referenced internal sales data and market intelligence feeds, enabling a holistic view of commercial performance across product types, clinical indications, end-user environments, and geographies.

Converging Insights and Strategic Outlook

The peripheral arterial disease therapeutics market stands at an inflection point, with scientific breakthroughs, policy shifts, and patient-centric care models driving accelerated transformation. Segmentation clarity reveals precisely where unmet clinical needs align with commercial potential, while regional analysis underscores the necessity of tailored market entry and access strategies. Competitive intelligence highlights the importance of strategic alliances, diversified pipelines, and digital integration in sustaining leadership positions.

Moving forward, organizations that embrace supply chain resilience, evidence-based value demonstration, and adaptive pricing frameworks will be best positioned to capitalize on emerging opportunities. The convergence of pharmacologic and interventional modalities offers a pathway to improved patient outcomes, but requires coordinated investment and cross-functional collaboration. By aligning R&D, market access, and digital health initiatives, stakeholders can deliver holistic care solutions that meet the evolving expectations of patients, providers, and payers alike.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Anticoagulants
      • Direct Oral Anticoagulants
      • Heparin
      • Warfarin
    • Antiplatelet Agents
      • Aspirin
      • Clopidogrel
      • Ticagrelor
    • Thrombolytics
      • Tissue Plasminogen Activator
      • Urokinase
    • Vasodilators
      • Cilostazol
      • Pentoxifylline
  • Indication
    • Critical Limb Ischemia
    • Intermittent Claudication
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Route Of Administration
    • Oral
    • Parenteral
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic plc
  • Terumo Corporation
  • Johnson & Johnson
  • Becton, Dickinson and Company
  • Koninklijke Philips N.V.
  • Cardiovascular Systems, Inc.
  • Merit Medical Systems, Inc.
  • Teleflex Incorporated

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peripheral Arterial Disease Therapeutics Market, by Product Type
8.1. Introduction
8.2. Anticoagulants
8.2.1. Direct Oral Anticoagulants
8.2.2. Heparin
8.2.3. Warfarin
8.3. Antiplatelet Agents
8.3.1. Aspirin
8.3.2. Clopidogrel
8.3.3. Ticagrelor
8.4. Thrombolytics
8.4.1. Tissue Plasminogen Activator
8.4.2. Urokinase
8.5. Vasodilators
8.5.1. Cilostazol
8.5.2. Pentoxifylline
9. Peripheral Arterial Disease Therapeutics Market, by Indication
9.1. Introduction
9.2. Critical Limb Ischemia
9.3. Intermittent Claudication
10. Peripheral Arterial Disease Therapeutics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Peripheral Arterial Disease Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Oral
11.3. Parenteral
12. Americas Peripheral Arterial Disease Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Peripheral Arterial Disease Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Peripheral Arterial Disease Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Abbott Laboratories
15.3.2. Boston Scientific Corporation
15.3.3. Medtronic plc
15.3.4. Terumo Corporation
15.3.5. Johnson & Johnson
15.3.6. Becton, Dickinson and Company
15.3.7. Koninklijke Philips N.V.
15.3.8. Cardiovascular Systems, Inc.
15.3.9. Merit Medical Systems, Inc.
15.3.10. Teleflex Incorporated
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 55. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 56. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 57. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 58. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 128. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 129. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 130. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 131. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 184. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 185. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 186. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 187. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 248. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 249. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 250. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 251. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 273. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 274. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2030 (USD MILLION)
TABLE 275. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2030 (USD MILLION)
TABLE 276. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. INDIA PERIPHERAL ARTERIAL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Peripheral Arterial Disease Therapeutics market report include:
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic plc
  • Terumo Corporation
  • Johnson & Johnson
  • Becton, Dickinson and Company
  • Koninklijke Philips N.V.
  • Cardiovascular Systems, Inc.
  • Merit Medical Systems, Inc.
  • Teleflex Incorporated

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.55 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report - Product Image

Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report

  • Report
  • 188 Pages
  • Global
From
Peripheral Arterial Disease Market Report 2025 - Product Image

Peripheral Arterial Disease Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Peripheral Artery Disease Market Report 2025 - Product Image

Peripheral Artery Disease Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Peripheral Artery Disease Market Report by Type Filters, End User, and Region 2024-2032 - Product Image

Peripheral Artery Disease Market Report by Type Filters, End User, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Peripheral Artery Disease Market Size, Share & Trends Analysis Report By Product Type (Drugs, and Devices), By End User (Hospitals, and Specialty Clinics), By Regional Outlook and Forecast, 2024 - 2031 - Product Image

Peripheral Artery Disease Market Size, Share & Trends Analysis Report By Product Type (Drugs, and Devices), By End User (Hospitals, and Specialty Clinics), By Regional Outlook and Forecast, 2024 - 2031

  • Report
  • 295 Pages
  • Global
From

About the Peripheral Artery Disease Drug Market

Peripheral Artery Disease (PAD) is a cardiovascular disorder caused by the narrowing of arteries in the legs, leading to reduced blood flow and oxygen supply. PAD is a major cause of disability and death, and is often treated with drugs. Commonly prescribed drugs for PAD include antiplatelet agents, anticoagulants, statins, and vasodilators. Antiplatelet agents reduce the risk of blood clots, while anticoagulants prevent the formation of clots. Statins are used to reduce cholesterol levels, while vasodilators widen the arteries and improve blood flow. The PAD drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of PAD, the development of new drugs, and the rising demand for better treatments. The market is expected to grow at a steady rate in the coming years, driven by the increasing prevalence of PAD and the development of new drugs. Some of the major companies in the PAD drug market include Pfizer, Merck, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.